229 related articles for article (PubMed ID: 16932898)
1. FGF23: its role in renal bone disease.
Fukagawa M; Kazama JJ
Pediatr Nephrol; 2006 Dec; 21(12):1802-6. PubMed ID: 16932898
[TBL] [Abstract][Full Text] [Related]
2. What would we like to know, and what do we not know about fibroblast growth factor 23?
Cozzolino M; Galassi A; Apetrii M; Covic A
J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
[TBL] [Abstract][Full Text] [Related]
3. FGF23: a key player in mineral and bone disorder in CKD.
Komaba H; Fukagawa M
Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750
[TBL] [Abstract][Full Text] [Related]
4. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
Komaba H
Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
[TBL] [Abstract][Full Text] [Related]
5. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
7. New insights into the role of fibroblast growth factor 23 in chronic kidney disease.
Nakai K; Komaba H; Fukagawa M
J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451
[TBL] [Abstract][Full Text] [Related]
8. Regulation of parathyroid function in chronic kidney disease (CKD).
Fukagawa M; Nakanishi S; Fujii H; Hamada Y; Abe T
Clin Exp Nephrol; 2006 Sep; 10(3):175-9. PubMed ID: 17009074
[TBL] [Abstract][Full Text] [Related]
9. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
[TBL] [Abstract][Full Text] [Related]
10. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
Hasegawa H; Nagano N; Urakawa I; Yamazaki Y; Iijima K; Fujita T; Yamashita T; Fukumoto S; Shimada T
Kidney Int; 2010 Nov; 78(10):975-80. PubMed ID: 20844473
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
12. [Kidney and bone update : the 5-year history and future of CKD-MBD. CKD-MBD and phosphotropic hormones].
Fukumoto S
Clin Calcium; 2012 Jul; 22(7):987-91. PubMed ID: 22750930
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
[TBL] [Abstract][Full Text] [Related]
14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
15. Role of fibroblast growth factor 23 in health and in chronic kidney disease.
Fukagawa M; Nii-Kono T; Kazama JJ
Curr Opin Nephrol Hypertens; 2005 Jul; 14(4):325-9. PubMed ID: 15930999
[TBL] [Abstract][Full Text] [Related]
16. Klotho gene, phosphocalcic metabolism, and survival in dialysis.
Torres PU; Prié D; Beck L; De Brauwere D; Leroy C; Friedlander G
J Ren Nutr; 2009 Jan; 19(1):50-6. PubMed ID: 19121771
[TBL] [Abstract][Full Text] [Related]
17. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
[TBL] [Abstract][Full Text] [Related]
18. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
19. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
20. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
Evenepoel P; Rodriguez M; Ketteler M
Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
